We and others have demonstrated that blocking the GLP1RA-induced GFRAL→CGRPelPBN pathway with another incretin, glucose-dependent insulinotropic polypeptide, removes the aversive element of treatment without reversing the anorexia19,25, which has important implications in the development of obesity drugs. Here, GCG is linked to obesity due to melanocortin 4 receptor deficiency.